Wednesday, March 31, 2021

Erasca Adds Two To Board

San Diego-based Erasca, which is working on treatments for cancer--backed by more than $320 million in financing from ARCH Venture Partners, City Hill Ventures and Cormorant Asset Management, along with others--said it has added two members to its board of directors. The company said it added Bihua Chen and Julie Hambleton, M.D., to board. Ms. Chen is a portfolio manager at Cormorant Asset Management, and Dr. Hambleton previously was interim CEO at Arch Oncology, as well as senior vice president, chief medical officer, and head of development at IDEAYA Biosciences, in addition to serving at Bristol-Myers Squibb.